Lonza | LONN - Equity Capital And Reserves


Lonza reported CHF9.13B in Equity Capital and Reserves for its fiscal semester ending in December of 2025.





Equity Capital And Reserves Change Date
Akzo Nobel EUR 4.88B 222M Mar/2026
Alcon AG USD 22.13B 99M Mar/2026
Almirall EUR 1.49B 24.03M Dec/2025
AstraZeneca USD 47.33B 1.33B Mar/2026
BASF EUR 33.2B 434M Dec/2025
Bayer EUR 28.85B 2.9B Mar/2026
Beiersdorf EUR 8.6B 133M Dec/2025
Covestro EUR 7B 908M Dec/2025
Demant DKK 9.84B 446M Dec/2025
Fresenius EUR 19.77B 1.14B Dec/2025
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Geberit CHF 1.54B 237.4M Mar/2025
Genmab DKK 5.85B 96M Dec/2025
Givaudan CHF 4.54B 430M Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
GN Store Nord DKK 10.12B 4.76B Mar/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Johnson Matthey GBP 2.02B 85M Jun/2026
Merck EUR 29.74B 1.15B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Philips EUR 11.39B 403M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Sika AG CHF 6.66B 481.4M Dec/2025
Smith & Nephew USD 5.54B 331M Dec/2025
Solvay EUR 1.18B 161M Mar/2026
UCB EUR 10.87B 1.18B Dec/2025